Pfizer said its targeted cancer drug Xalkori trounced chemotherapy in a trial of previously untreated patients with a particular type of lung cancer. The study showed for the first time that up-front treatment with Xalkori staves off cancer growth better than other treatments in patients whose tumors test positive for ALK-gene abnormalities.
More than two years ago Roche CEO Severin Schwan picked the cancer drug MetMAb out of the pipeline as one of the company's top blockbuster prospects. But on Monday its oncology R&D arm at Genentech was forced to halt a Phase III combo study matching MetMAb with Tarceva in a failed effort to block metastasis in non-small cell lung cancer after an independent monitoring group flagged the attempt for futility.
When BMS said it would continue its mid-stage instead of diving into a late-stage program testing nivolumab with melanoma hit Yervoy, investors feared it could mean problems with the combo--and sent shares down nearly 6%.
Lung cancer spreads quickly, which helps it claim more lives each year than any other cancer worldwide and makes early detection key. Now, two companies have teamed up to bring a diagnostic test to some of the countries that need it most.
Researchers on the lookout for ways to help detect one of the world's deadliest cancers may have a new biomarker on their hands. In lung cancer patients, scientists have linked the presence in tumors of the protein C4d to a higher cancer mortality rate, a new study says.
A biomarker detectable in the breath of lung cancer patients holds promise for an accurate diagnostic, and researchers at the Cleveland Clinic have taken another stride toward making that a reality.
Biotech Clovis Oncology is tapping Qiagen's diagnostic expertise as it develops an EGFR-targeting lung cancer treatment, tasking the German company with creating a companion test that can identify patients for clinical trials and, eventually, be sold alongside the drug.
Using a bioinformatics method involving a computerized discovery pipeline, researchers have found a possible new treatment for a deadly kind of lung cancer from existing drugs--a little-used class of antidepressants already approved by the FDA.
Clinically effective but not cost-effective. That's what U.K. watchdogs have determined about Pfizer's targeted lung cancer drug, Xalkori. Despite a discount offer from Pfizer, the National Institute for Health and Care Excellence still believes Xalkori isn't a good value.
That makes two "breakthrough" tags for the Swiss drugmaker so far.